Profile
Epidemiologist with over 20 years of international experience (Slovenia, Netherlands, Denmark, UK) in academia and over 100 published manuscripts. Skilled in leading multidisciplinary research with academic, clinical, public policy, patient advocacy, and industry collaborators. Committed to delivering accurate and transparent real-world health evidence, with a track record of research influencing NHS cancer screening policies. Dedicated, experienced mentor, supporting students and early-career researchers, including non-native English speakers, toward academic and professional success.
Research
Research Interests:
Topics:
Evaluation of population-based cancer screening programmes
Implementation of cancer screening interventions
Methods to evaluate screening programmes and tests
Methods:
Analysis of data from administrative data registers and clinical studies
Systematic and scoping reviews
Meta-analyses
Publications
1: Rebolj M, Brentnall AR, Cuschieri K. Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening. Br J Cancer 2024;130(11):1733-1743. doi: 10.1038/s41416-024-02681-z. Link: https://pubmed.ncbi.nlm.nih.gov/38615108/.
2: Brentnall AR, Cuschieri K, Sargent A, Berkhof J, Rebolj M. Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening. J Clin Epidemiol 2024;166:111227. doi: 10.1016/j.jclinepi.2023.111227. Link: https://pubmed.ncbi.nlm.nih.gov/38065518/.
3: Rebolj M, Sargent A, Njor SH, Cuschieri K. Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly. Int J Cancer 2023;153(1):8-19. doi: 10.1002/ijc.34358. Link: https://pubmed.ncbi.nlm.nih.gov/36385698/.
4: Rebolj M, Cuschieri K, Mathews CS, Pesola F, Denton K, Kitchener H; HPV pilot steering group. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ 2022;377:e068776. doi: 10.1136/bmj-2021-068776. Link: https://pubmed.ncbi.nlm.nih.gov/35640960/.
5: Rebolj M, Parmar D, Maroni R, Blyuss O, Duffy SW. Concurrent participation in screening for cervical, breast, and bowel cancer in England. J Med Screen 2020;27(1):9-17. doi: 10.1177/0969141319871977. Link: https://pubmed.ncbi.nlm.nih.gov/31525303/.
Supervision
Emily Lane
Funding: MRC-NIHR Trials Methodology Partnership
Working title: Surrogate endpoints for cancer screening trials
